Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Aspire Biopharma Holdings ( (ASBP) ) is now available.
On February 6, 2026, Aspire Biopharma Holdings, Inc. entered into a securities purchase agreement with select institutional and accredited investors for a private placement of up to 26,250 shares of Series A Convertible Preferred Stock, potentially raising gross proceeds of about $21 million. The preferred shares, which are convertible into common stock subject to caps and shareholder approvals, carried an initial closing on February 6, 2026, in which 13,750 shares were issued for $11 million, including the conversion of legacy debt.
The company said the financing, announced in a February 11, 2026 press release, is expected to strengthen its balance sheet, materially reduce outstanding indebtedness and bolster stockholders’ equity above Nasdaq’s minimum continued-listing threshold while it awaits formal confirmation of compliance. Aspire plans to use a portion of the proceeds to support legacy operations, fund strategic initiatives and advance development of its patent-pending drug delivery technologies, while investors also gain board representation through the right to appoint one director.
More about Aspire Biopharma Holdings
Aspire Biopharma Holdings, Inc. is a biopharmaceutical company developing multi-faceted, patent-pending sublingual drug delivery technology designed to deliver therapeutics rapidly and directly into the bloodstream. Its platform is intended to be applied across a range of active pharmaceutical ingredients, including small and large molecule drugs, nutraceuticals and supplements, with the aim of improving efficacy and reducing side effects.
The company’s technology targets precise, rapid systemic delivery by bypassing the gastrointestinal tract, positioning Aspire within the drug delivery innovation segment of the life sciences market. This focus on versatile sublingual formulations supports potential partnerships and applications across multiple therapeutic categories and consumer health products.
Average Trading Volume: 1,293,958
Technical Sentiment Signal: Sell
Current Market Cap: $4.88M
Learn more about ASBP stock on TipRanks’ Stock Analysis page.